
NICE recommends first treatment in two decades for sickle cell disease
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
All NICE products on blood conditions. Includes any guidance, advice and quality standards.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (6)
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (3)
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review new diagnostic technologies for adoption in the NHS.
Review clinical and cost-effectiveness of specialised treatments.
Reviews new medical devices for adoption in the NHS.
Review the best available evidence for selected medicines.
Review the evidence and likely costs of medical devices and technologies.
Guidance, quality standards and advice being developed.
Guidance and quality standards awaiting development.
Guidance in topic selection.
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 1 of 1 shared learning examples for this topic: